Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 4 1

Status

Unknown 2Terminated 1Recruiting 1Not yet recruiting 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 3

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Gastrointestinal 2Gynecologic 1

Conditions

Triple Negative Breast Neoplasms 11Breast Neoplasms 6Stomach Neoplasms 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasms, Unknown Primary 1Mesothelioma 1Melanoma 1Leukemia, Myeloid, Acute 1Hypersensitivity 1HER2-negative Breast Cancer 1Endometrial Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Carcinoma 1Anus Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

Trastuzumab 628Paclitaxel 577Cyclophosphamide 555Docetaxel 485Capecitabine 402Letrozole 376Fulvestrant 327Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 186Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 139Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Breast Neoplasms × tislelizumab × Breast × Clear all
NCT04577963 2025-07-14

A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
52 enrolled 23 charts
BreastGastrointestinalGynecologic

Breast Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

BeiGene

Phase 1/2 Completed
71 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT06471673 2024-08-26

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

BriaCell Therapeutics Corporation

Phase 1/2 Recruiting
18 enrolled
Breast

Breast Neoplasms

NCT06547476 2024-08-09

Chidamide and PD-1 Inhibitor Plus Anlotinib for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed

Guangdong Provincial People's Hospital

Phase 2 Not yet recruiting
40 enrolled
Breast

Breast Neoplasms

NCT04734262 2023-11-18

SPARK

Fudan University

Phase 2 Unknown
98 enrolled
Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05861635 2023-05-17

The Study of Vidicizumab Combined With Tirelizumab in the Treatment of Breast Cancer With Low HER2 Expression

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 4 Unknown
42 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡